Stay updated with breaking news from Sciad Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IRVING, Texas, Oct. 19, 2021 /PRNewswire/ -- Darling Ingredients Inc.'s (NYSE: DAR) health brand, Rousselot, the global leader of collagen-based solutions, today launches Quali-Pure, a range
Solentim expands European operations May 4, 2021 Bournemouth, UK, 5th May 2021 / Sciad Newswire / Solentim, the trusted global leader in workflows for antibody and cell-based therapies, today announced an expansion of its European operations. The company has established a new EU entity based in Ireland to facilitate frictionless business within the EU. Additionally, Solentim has opened a new warehousing and logistics hub in Germany, to better serve its customers within the EU. Solentim’s CEO, Dr Mark Truesdale, commented, “Europe is a fast-growing part of our...
Darling Ingredients Inc. (NYSE: DAR) today announced that its Rousselot brand, the global leader of collagen-based solutions, expands its range of purified, pharmaceutical grade, modified gelatins with the launch of X-Pure® GelDAT – Gelatin Desaminotyrosine. Created in response to customer's demand to overcome the barriers encountered in clinical translation, this is the first, readily available biomaterial of its kind. X-Pure® GelDAT offers guaranteed purity and consistency at scale, vital to the successful development of biomedical applications used in the human body.
Future Planet Capital: Future Planet Invests in Vaccitech's Series B Financing Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168 million before expenses. Do...